Lu, Shun http://orcid.org/0000-0001-8833-7262
Pan, Hongming
Wu, Lin
Yao, Yu
He, Jianxing
Wang, Yan
Wang, Xiuwen
Fang, Yong
Zhou, Zhen
Wang, Xicheng
Cai, Xiuyu
Yu, Yan
Ma, Zhiyong
Min, Xuhong
Yang, Zhixiong
Cao, Lejie
Yang, Huaping
Shu, Yongqian
Zhuang, Wu
Cang, Shundong
Fang, Jian
Li, Kai
Yu, Zhuang
Cui, Jiuwei
Zhang, Yang
Li, Man
Wen, Xinxuan
Zhang, Jie
Li, Weidong
Shi, Jianhua
Xu, Xingxiang
Zhong, Diansheng
Wang, Tao
Zhu, Jiajia
Article History
Received: 21 October 2022
Revised: 9 February 2023
Accepted: 20 April 2023
First Online: 30 June 2023
Competing interests
: S.L. has received research support from Astra Zeneca, Hutchison, BMS, Heng Rui, Beigene and Roche, Hansoh, Lilly Suzhou Pharmaceutical Co. Ltd; has received speaker fees from Astra Zeneca, Roche, Hansoh, Hengrui Therapeutics; and is an advisor and consultant of Astra Zeneca, Pfizer, Boehringer Ingelheim, Hutchison MediPharma, ZaiLab, GenomiCare, Yuhan Corporation, Menarini, InventisBio Co. Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Simcere Zaiming Pharmaceutical Co., Ltd. and Roche. T.W. and J.Z. are employees of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. All the other authors declare no competing interests.